Post-Reperfusion Pathophysiology in Acute Ischemic Stroke

Not Applicable

Completed

• Conditions: stroke; Stroke - Ischaemic

• Registration Number: ACTRN12624000629538
• Lead Sponsor: Melbourne Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-03-22
• Study Start: 2024-05-15
• Last Update Posted: 21 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

Adult patients (>18 years-old) presenting for or receiving reperfusion therapies (e.g. thrombectomy) for acute ischaemic stroke with anterior circulation large vessel occlusion.

Exclusion Criteria

Exclusions include inability to give informed consent, contraindications to MRI study (eg. metallic foreign bodies in situ, claustrophobia, pregnancy), medical instability, terminal illness with expected survival less than 1 year.
Specific MRI sequences involving Gadolinum will be omitted for patients with significant renal impairment (eGFR <30 ml/min) as per standard practice for the studies.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MRI perfusion metrics assessed as composite primary outcome (e.g. Cerebral Blood Volume, Cerebral Blood Flow, Blood Brain Barrier Permeability)[DSC-MRI <2hr post-treatment, 24-72hours, 3 months, 12 months]

Secondary Outcome Measures

Name	Time	Method
Modified Rankin Scale[Clinical assessment using the modified Rankin Scale by certified investigator 3-month, 12-months];Multimodal MRI metrics as composite secondary outcome<br>(e.g. diffusion FA/MD/ADC)[MRI <2hr post-treatment, 24-72hours, 3 months, 12 months]